12 Biotech Stocks with the Biggest Upside Potential

Page 8 of 11

4. Merus N.V. (NASDAQ:MRUS)

Analyst Upside: 122.95%

Number of Hedge Fund Holders: 48

Merus N.V. (NASDAQ:MRUS) is a clinical-stage immuno-oncology company that discovers and develops bispecific antibody therapeutics. Its product pipeline includes Biclonics to treat solid and hematological tumors. On January 12, the company announced a research collaboration and license agreement with Biohaven Ltd. (NYSE:BHVN) to co-develop three novel bispecific antibody-drug conjugates (ADCs). The partnership is expected to expand the company’s portfolio.

The company attained FDA approval for its BIZENGRI® (zenocutuzumab-zbco) drug, the first and only treatment for adults with pancreatic adenocarcinoma or non–small cell lung cancer (NSCLC). This put the company on a positive trajectory.

Merus N.V. (NASDAQ:MRUS) strengthened its financial position in fiscal Q3 2024. It reported $433 million in cash and cash equivalents, up from $204 million at the end of 2023. This growth was attributed to successful public offerings and strategic partnerships. Merus N.V. (NASDAQ:MRUS) ranks fourth on our list of the 12 biotech stocks with the biggest upside potential.

TimesSquare Capital Management U.S. Small Cap Growth Strategy stated the following regarding Merus N.V. (NASDAQ:MRUS) in its Q2 2024 investor letter:

“Our preferences among Health Care stocks are those companies providing novel therapies for unmet needs that deserve premium pricing, or specialized service providers. A new addition this quarter is Merus N.V. (NASDAQ:MRUS), a clinical-stage immune-oncology biotechnology company. Their pipeline consists of several programs targeting solid tumors with various bispecific antibodies.”

Page 8 of 11